NCT02652572View on ClinicalTrials.gov

Safety Study to Examine the Systemic Exposure of Granexin® Gel After Topical Application to Venous Leg Ulcers

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

December 31, 2017

Study Completion Date

May 31, 2018

Conditions
Venous Leg Ulcer
Interventions
DRUG

Granexin

Granexin® gel will be dispensed directly from a 5 gram laminate tube and will be spread and smoothed directly over the wound surface in full contact with the wound bed to obtain an even, uniform layer on Day 0 (baseline), Day 3, and Day 7.

Trial Locations (3)

24153

Salem VA Medical Center, Salem

29303

Spartanburg Regional Healthcare System, Spartanburg

30907

Aiyan Diabetes Center, Augusta

All Listed Sponsors
collaborator

Spartanburg Regional Healthcare System

OTHER

collaborator

Medical University of South Carolina

OTHER

lead

Xequel Bio, Inc.

OTHER

NCT02652572 - Safety Study to Examine the Systemic Exposure of Granexin® Gel After Topical Application to Venous Leg Ulcers | Biotech Hunter | Biotech Hunter